Mostrar el registro sencillo del ítem

dc.contributor.author
Crispo, James A. G.
dc.contributor.author
Willis, Allison W.
dc.contributor.author
Thibault, Dylan P.
dc.contributor.author
Fortin, Yannick
dc.contributor.author
Hays, Harlen D.
dc.contributor.author
McNair, Douglas S.
dc.contributor.author
Bjerre, Lise M.
dc.contributor.author
Kohen, Dafna E.
dc.contributor.author
Pérez Lloret, Santiago
dc.contributor.author
Mattison, Donald R.
dc.contributor.author
Krewski, Daniel
dc.date.available
2019-09-27T17:16:52Z
dc.date.issued
2016-03
dc.identifier.citation
Crispo, James A. G.; Willis, Allison W.; Thibault, Dylan P.; Fortin, Yannick; Hays, Harlen D.; et al.; Associations between anticholinergic burden and adverse health outcomes in Parkinson disease; Public Library of Science; Plos One; 11; 3; 3-2016; 21-28; e0150621
dc.identifier.uri
http://hdl.handle.net/11336/84674
dc.description.abstract
Background Elderly adults should avoid medications with anticholinergic effects since they may increase the risk of adverse events, including falls, delirium, and cognitive impairment. However, data on anticholinergic burden are limited in subpopulations, such as individuals with Parkinson disease (PD). The objective of this study was to determine whether anticholinergic burden was associated with adverse outcomes in a PD inpatient population. Methods Using the Cerner Health Facts1database, we retrospectively examined anticholinergic medication use, diagnoses, and hospital revisits within a cohort of 16,302 PD inpatients admitted to a Cerner hospital between 2000 and 2011. Anticholinergic burden was computed using the Anticholinergic Risk Scale (ARS). Primary outcomes were associations between ARS score and diagnosis of fracture and delirium. Secondary outcomes included associations between ARS score and 30-day hospital revisits. Results Many individuals (57.8%) were prescribed non-PD medications with moderate to very strong anticholinergic potential. Individuals with the greatest ARS score (4) were morelikely to be diagnosed with fractures (adjusted odds ratio (AOR): 1.56, 95% CI: 1.29-1.88) and delirium (AOR: 1.61, 95% CI: 1.08-2.40) relative to those with no anticholinergic burden. Similarly, inpatients with the greatest ARS score were more likely to visit the emergency department (adjusted hazard ratio (AHR): 1.32, 95% CI: 1.10-1.58) and be readmitted (AHR: 1.16, 95% CI: 1.01-1.33) within 30-days of discharge. Conclusions We found a positive association between increased anticholinergic burden and adverse outcomes among individuals with PD. Additional pharmacovigilance studies are needed to better understand risks associated with anticholinergic medication use in PD.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Public Library of Science
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Enfermedad de Parkinson
dc.subject
Medicamentos Anticolinérgicos
dc.subject
Delirio
dc.subject
Fracturas
dc.subject.classification
Epidemiología
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Associations between anticholinergic burden and adverse health outcomes in Parkinson disease
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-08-30T13:56:51Z
dc.identifier.eissn
1932-6203
dc.journal.volume
11
dc.journal.number
3
dc.journal.pagination
21-28; e0150621
dc.journal.pais
Estados Unidos
dc.journal.ciudad
San Francisco
dc.description.fil
Fil: Crispo, James A. G.. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos
dc.description.fil
Fil: Thibault, Dylan P.. University of Pennsylvania; Estados Unidos. University of Ottawa; Canadá
dc.description.fil
Fil: Fortin, Yannick. University of Ottawa; Canadá
dc.description.fil
Fil: Hays, Harlen D.. Cerner Corporation; Estados Unidos
dc.description.fil
Fil: McNair, Douglas S.. Cerner Corporation; Estados Unidos
dc.description.fil
Fil: Bjerre, Lise M.. University of Ottawa; Canadá
dc.description.fil
Fil: Kohen, Dafna E.. University of Ottawa; Canadá
dc.description.fil
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
dc.description.fil
Fil: Mattison, Donald R.. University of Ottawa; Canadá. Risk Sciences International; Canadá
dc.description.fil
Fil: Krewski, Daniel. University of Ottawa; Canadá. Risk Sciences International; Canadá
dc.journal.title
Plos One
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1371/journal.pone.0150621
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150621


Archivos asociados

 

Comunidades y colecciones

Mostrar el registro sencillo del ítem